Invite someone you know to join Pharmalicensing.com
Change Password
PL Stealth Mode
Go Incognito on Pharmalicensing.
All interaction tracking will be disabled, rendering you invisible to other Pharmalicensing users and technology providers.
Stealth Mode currently OFF.
Included with Premium accounts. Add-on upgrade to Plus accounts.
Register
or
Sign in
to Save this opportunity, or Send an Inquiry.
You must be signed in to send an inquiry.
Please Register or Login to save this technology and benefit from all of Pharmalicensing's features.
Select to Save this to or Remove this from an Existing Collection
Development of New Methods for Haematopoietic Precursors Mobilization
Yeda R&D Co. LtdIsrael
Abstract ID: 1545
The forced migration of hematopoietic stem/progenitor cells (HSPC) from the bone marrow (BM) into the peripheral blood (PB), termed mobilization, is important from a clinical point of view
Send an Inquiry
Introduction/Background
The forced migration of hematopoietic stem/progenitor cells (HSPC) from the bone marrow (BM) into the peripheral blood (PB), termed mobilization, is important from a clinical point of view as a procedure that allows for the collection of HSPC for transplantation in leukaemia patients. Granulocyte-colony stimulating factor (G-CSF), most frequently employed in the clinic, efficiently mobilizes HSPC after a few consecutive daily injections. Unfortunately, about 25 % of patients do not respond efficiently to currently recommended mobilization protocols and are termed poor mobilizers.
Aims/Hypothesis
The present invention provides a method of increasing mobilization of hematopoietic precursors from the bone marrow to the peripheral blood, by using either G-CSF with thrombin antagonists, or the antagonists alone.
Results
In the outlined technology it was found that enhancement of G-CSF levels is associated with enhancement of stem cell mobilization from the bone marrow to the spleen. Likewise, inhibitors of the interaction between thrombin and its receptors (known as PAR) could enhance the effect of G-CSF. Therefore, PAR antagonists are synergistic with G-CSF, leading to marked enhancement of stem cell mobilization. Considering that G-CSF is controversial due to several side effects, this invention might enable using lower doses of G-CSF or replace it altogether by thrombin antagonists. The currently lengthy procedure may be shortened using this invention.
Conclusion
We have developed a method for increasing the mobilization of hematopoietic stem cells.
Relevance/Opportunity
Treatment of cancer, by upregulation of a factor of the coagulation cascade and inhibition of mobilization (since solid tumours depend on bone marrow-derived cells for tumour vascularisation and survival). Please enquire quoting reference no. 1545 regarding licensing or codevelopment partnerships.
Clinical Trial Information (0)Hide
FEATURED
Last Updated May 2015
PLATFORM
CLINICAL TRIALS
CORPORATION
Yeda R&D Co. Ltd
Weizmann Institute of Science
P.O Box 95,
Rehovot 76100
Israel